HC Wainwright Has Optimistic Outlook of SNDX Q2 Earnings

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) – Research analysts at HC Wainwright raised their Q2 2026 earnings per share (EPS) estimates for shares of Syndax Pharmaceuticals in a research report issued on Friday, May 1st. HC Wainwright analyst A. Maldonado now forecasts that the company will post earnings of ($0.33) per share for the quarter, up from their previous forecast of ($0.44). The consensus estimate for Syndax Pharmaceuticals’ current full-year earnings is ($1.65) per share. HC Wainwright also issued estimates for Syndax Pharmaceuticals’ Q3 2026 earnings at ($0.21) EPS, Q4 2026 earnings at ($0.13) EPS, FY2026 earnings at ($1.16) EPS, FY2027 earnings at ($0.13) EPS, FY2028 earnings at $1.17 EPS and FY2029 earnings at $2.59 EPS.

Syndax Pharmaceuticals (NASDAQ:SNDX) last released its quarterly earnings data on Thursday, April 30th. The company reported ($0.48) earnings per share for the quarter, beating the consensus estimate of ($0.59) by $0.11. Syndax Pharmaceuticals had a negative return on equity of 216.23% and a negative net margin of 111.88%.The business had revenue of $64.86 million for the quarter, compared to analysts’ expectations of $69.76 million. During the same quarter in the previous year, the business posted ($0.98) EPS. Syndax Pharmaceuticals’s revenue for the quarter was up 224.3% on a year-over-year basis.

Other equities analysts have also recently issued research reports about the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Syndax Pharmaceuticals in a report on Friday, March 27th. Jefferies Financial Group reiterated a “buy” rating and set a $40.00 price objective (down from $48.00) on shares of Syndax Pharmaceuticals in a report on Monday, March 30th. JPMorgan Chase & Co. lifted their price objective on Syndax Pharmaceuticals from $33.00 to $45.00 and gave the company an “overweight” rating in a report on Monday, March 9th. Barclays lifted their price objective on Syndax Pharmaceuticals from $35.00 to $37.00 and gave the company an “overweight” rating in a report on Friday. Finally, The Goldman Sachs Group lifted their price objective on Syndax Pharmaceuticals from $28.00 to $34.00 and gave the company a “buy” rating in a report on Wednesday, April 1st. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $40.50.

Syndax Pharmaceuticals Trading Up 4.4%

NASDAQ:SNDX opened at $19.96 on Tuesday. Syndax Pharmaceuticals has a fifty-two week low of $8.58 and a fifty-two week high of $25.59. The company has a debt-to-equity ratio of 5.32, a current ratio of 4.40 and a quick ratio of 4.12. The stock has a market capitalization of $1.76 billion, a PE ratio of -7.15 and a beta of 0.42. The business’s 50-day simple moving average is $23.03 and its 200-day simple moving average is $20.43.

Institutional Investors Weigh In On Syndax Pharmaceuticals

Several institutional investors have recently bought and sold shares of the company. Sector Gamma AS bought a new stake in shares of Syndax Pharmaceuticals during the 3rd quarter worth approximately $3,243,000. Apis Capital Advisors LLC bought a new stake in shares of Syndax Pharmaceuticals during the 3rd quarter worth approximately $9,816,000. Torray Investment Partners LLC bought a new stake in shares of Syndax Pharmaceuticals during the 4th quarter worth approximately $2,055,000. Palumbo Wealth Management LLC bought a new stake in shares of Syndax Pharmaceuticals during the 4th quarter worth approximately $1,079,000. Finally, Keybank National Association OH bought a new stake in shares of Syndax Pharmaceuticals during the 3rd quarter worth approximately $2,305,000.

Insider Activity at Syndax Pharmaceuticals

In other Syndax Pharmaceuticals news, CFO Keith A. Goldan sold 3,410 shares of the business’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $21.03, for a total value of $71,712.30. Following the sale, the chief financial officer owned 140,429 shares in the company, valued at approximately $2,953,221.87. The trade was a 2.37% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Michael A. Metzger sold 17,159 shares of the business’s stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $21.03, for a total value of $360,853.77. Following the completion of the sale, the chief executive officer owned 491,690 shares in the company, valued at $10,340,240.70. The trade was a 3.37% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 30,063 shares of company stock worth $628,332 in the last 90 days. Company insiders own 4.10% of the company’s stock.

Syndax Pharmaceuticals News Summary

Here are the key news stories impacting Syndax Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright materially raised near- and long-term EPS assumptions, trimming projected losses for 2026 and forecasting a path to profitability in later years. The firm’s analyst A. Maldonado now models FY2026 EPS of ($1.16) (prior -$1.66), Q2 2026 ($0.33) from ($0.44), Q3 2026 ($0.21) from ($0.38), and Q4 2026 ($0.13) from ($0.34). They also lifted FY2028 to $1.17 (from $0.91) and FY2029 to $2.59 (from $2.14). This set of upgrades signals faster revenue/profit ramp in the model and supports upside to the stock. MarketBeat SNDX
• Positive Sentiment: AmericanBankingNews published a bullish piece summarizing HC Wainwright’s longer-term upside (FY2030 outlook), reinforcing investor attention on SNDX’s modeled return-to-profitability beyond 2028. HC Wainwright Has Bullish Outlook for SNDX FY2030 Earnings
• Negative Sentiment: Offsetting the mostly upward revisions, HC Wainwright slightly lowered its FY2027 EPS forecast to ($0.13) from ($0.08), indicating some timing uncertainty in the firm’s model between the near-term recovery and later profitability — a modest negative for pacing expectations. MarketBeat SNDX

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for the treatment of cancer. Headquartered in Waltham, Massachusetts, the company focuses on small-molecule inhibitors that target key epigenetic and protein interaction pathways. Syndax’s research platform aims to enhance the effectiveness of existing therapies and address high unmet medical needs in oncology.

The company’s lead investigational candidate, entinostat, is a selective class I histone deacetylase (HDAC) inhibitor being evaluated for multiple solid tumor and hematologic indications.